Finding or detecting cancer at an early stage can make it much more treatable.  Molecular staging of cancer has the potential of being able to recognize subsets of the disease to allow for highly targeted therapies that can yield unprecedented results.  Commercial tests need to be able to diagnose cancer with an exquisite sensitivity with just a few cells, to overcome the challenge of the heterogeneity of cancer.  Plan to attend to learn what progress has been made towards developing assays with specific biomarkers to cancer that will create a new generation of products.

Technologies Include:          

• Addressing challenges with circulating tumor cells 
• Advances in deep sequencing of cancer
• Blood-based, non-invasive early detection 
• Detection of cancer related low abundance proteins
• Cancer-type specific vs. pan-cancer approaches
• Strategies for improved prognostic markers 
• Overcoming barriers to clinical adoption 
• Crossing reimbursement and regulatory hurdles

If you would like to submit a proposal to give a podium presentation or display a poster at this meeting, please click here to submit a title and brief 3-5 sentence summary of a proposed topic on your recent work in the area of cancer diagnostics. 

The deadline for submission is February 12, 2010. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the overall quality of the conference program.

For more information, please contact
Christina Lingham
Cambridge Healthtech Institute
250 First Ave, Suite 300
Needham, MA  02494
Tel: 781-972-5464
Fax: 781-972-5425
email: clingham@healthtech.com 

For information on sponsorships and exhibits, please contact:
Arnie Wolfson
Manager, Business Development
Tel: 781-972-5431
email: awolfson@healthtech.com